Sarepta Therapeutics Q1 Results Beat Expectations Despite Stock Decline

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 4 days ago

0mins

SRPT-4.06%

Should l Buy SRPT?

Source: seekingalpha

Strong Financial Performance: Sarepta Therapeutics reported a non-GAAP EPS of $3.16 for Q1, beating expectations by $2.11, indicating an improvement in profitability despite a year-over-year revenue decline.
Revenue Guidance Adjustment: The company projects net product revenues for 2026 to be between $1.2 billion and $1.4 billion, falling short of the consensus estimate of $1.73 billion, reflecting market caution regarding future growth.
Significant R&D Expense Reduction: R&D expenses for the quarter were $154 million, a substantial decrease from $773.4 million year-over-year, demonstrating effective cost control measures that have positively impacted overall financial health.
Cash Flow Status: As of the end of the quarter, the company had cash, cash equivalents, restricted cash, and investments totaling $748.3 million, down from $953.8 million on December 31, 2025, indicating a tightening of cash resources.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SRPT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SRPT

Wall Street analysts forecast SRPT stock price to rise

18 Analyst Rating

4 Buy

10 Hold

4 Sell

Hold

Current: 20.800

Low

5.00

Averages

20.80

High

45.00

Current: 20.800

Low

5.00

Averages

20.80

High

45.00

H.C. Wainwright

Mitchell Kapoor

Sell

maintain

2026-04-16

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

AI Analysis

2026-04-16

maintain

Sell

Reason

H.C. Wainwright analyst Mitchell Kapoor reiterates a Sell rating on Sarepta (SRPT) with a $5 price target saying Roche's (RHHBY) new placebo-controlled Phase 3 study raises the risk that Elevidys fails the North Star Ambulatory Assessment efficacy test again. The EMBARK study already failed to show statistical significance on NSAA, and Roche is trying again, the firm points out. Roche is now putting Elevidys "back into another randomized test that could further crack the external-control argument if NSAA misses again," the analyst tells investors in a research note. H.C. Wainwright believes this creates limited upside for Sarepta and meaningful downside for the U.S. franchise that still drives the shares. Sarepta's core revenue stream is the U.S. Elevidys business, not Europe, the firm contends.

RBC Capital

Sector Perform

maintain

$18 -> $19

2026-04-07

Reason

RBC Capital

Price Target

$18 -> $19

2026-04-07

maintain

Sector Perform

Reason

RBC Capital raised the firm's price target on Sarepta to $19 from $18 and keeps a Sector Perform rating on the shares as part of the firm's broader research note previewing Q1 results in Biotech. Seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in Q1 by weather impact, particularly for launching and in-clinic products, but the robust return of M&A, coupled with clarity on limited tariff/Most Favored Nation drug pricing impacts, could help offset both this and broader macro volatility while keeping sector perceptions favorable, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SRPT

Unlock Now

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

FDA Leadership Shakeup May Impact Biotech Stocks

2 days agostocktwits

Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.

Sarepta Therapeutics Q1 2026 Earnings Call Insights

3 days agoseekingalpha

Stable Financial Performance: Sarepta reported total net product revenue of $331 million in Q1 2026, with PMO therapies contributing $229 million and ELEVIDYS $102 million, indicating a gradual recovery in profitability following disruptions in 2025.
Guidance Reaffirmation: Management reiterated its 2026 net product revenue guidance of $1.2 billion to $1.4 billion, while emphasizing that the recovery of ELEVIDYS demand will be a slow process, reflecting a cautious approach to market dynamics.
Cash Flow and Investments: As of the end of Q1, Sarepta held approximately $748 million in cash and investments, achieving positive cash flow excluding Arrowhead-related payments, demonstrating the company's ability to fund its pipeline without reliance on equity markets.
Clinical Progress and Regulation: Sarepta is advancing standard approval applications for VYONDYS and AMONDYS, with a PDUFA date expected in February next year, showcasing the company's efforts to strengthen the regulatory standing of its product portfolio.

Sarepta's Q1 Results Beat Expectations but Shares Drop

4 days agostocktwits

Strong Performance: Sarepta Therapeutics reported Q1 total revenue of $730.8 million, which, despite a 2% year-over-year decline, exceeded market expectations of $475.01 million, demonstrating resilience in revenue generation.
Adjusted EPS Improvement: The company posted an adjusted earnings per share of $3.16, a significant recovery from a loss of $3.42 in the same quarter last year, and comfortably above the analyst estimate of $1.09, indicating a marked improvement in profitability.
Decline in Elevidys Sales: Elevidys generated $102 million in net product sales, a sharp drop from $375 million in Q1 2025, primarily due to safety concerns limiting the addressable patient population, which adversely affected the company's core business.
Future Guidance: Sarepta reiterated its full-year 2026 guidance for total net product revenue between $1.2 billion and $1.4 billion, and despite challenges, CEO Doug Ingram expressed optimism about the stabilization of the company's commercial portfolio and the growth potential of Elevidys.